Peptides for Hip Pain — Evidence-Based Overview

How peptide Targets Peptides for Hip Pain

Hip pain encompasses multiple distinct conditions that require different approaches: osteoarthritis of the hip joint (cartilage degeneration), trochanteric bursitis (inflammation of the bursa over the greater trochanter), hip labral tears (damage to the cartilage ring stabilizing the hip socket), gluteal tendinopathy, and hip impingement (FAI). The hip joint is a deep ball-and-socket structure with limited accessibility for topical treatments, making systemic and injectable peptide approaches more relevant than for superficial joints.

BPC-157 has preclinical evidence for multiple tissue types found in the hip: cartilage, tendon, ligament, and muscle. For hip osteoarthritis — the most common cause of hip pain in adults over 50 — BPC-157's chondroprotective effects in animal models are relevant. Studies suggest it may modulate inflammatory degradation of cartilage and support repair mechanisms. TB-500 (Thymosin Beta-4) complements this with anti-inflammatory and cell migration properties. Pentosan polysulfate (PPS) is particularly interesting for hip conditions because it has actual clinical use history in veterinary medicine for osteoarthritis and has been studied for joint health in humans. It inhibits cartilage-degrading enzymes and may support synovial fluid quality, though recent concerns about potential retinal toxicity with long-term use have tempered enthusiasm.

For hip bursitis and tendinopathy, the peptide approach mirrors that for other tendon and soft tissue conditions. BPC-157 and TB-500 address the inflammatory and repair aspects. Collagen peptides taken orally may support connective tissue quality throughout the hip region. Growth hormone secretagogues like Ipamorelin are sometimes included for their general tissue repair support through elevated GH/IGF-1, though targeting this systemic approach to a specific joint is inherently imprecise. For labral tears, which involve fibrocartilage damage in a structure with limited blood supply, the biological challenge is similar to meniscal tears in the knee — repair capacity is limited, and peptides may support healing environment but cannot replace surgical intervention when structural repair is indicated. Physical therapy addressing hip stability, mobility, and biomechanics remains foundational regardless of peptide use.